New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2009
Alzheimer’s and Parkinson’s Disease AD/PD
Prague, Czech Republic, March 11-15, 2009
InternatIonal ProceedIngs
MEDIMOND S.r.l. • Via Maserati 5, 40128 Bologna, Italy
InternatIonal ProceedIngs dIvIsIon
Tel. +39 0514151111 • Fax +39 051 4151125
All rights reserved. No part of this publication may be reproduced,
stored in a retrieval system, or transmitted, in any form,
or by any means, electronic, mechanical, photocopying,
recording or otherwise, without the prior permission,
Printed in October 2009 by Editografica • Rastignano • Bologna (Italy)
Foreword
This is the fourth book of what is becoming a series of companion pieces to the
bi-annual conferences on Alzheimer’s and Parkinson’s diseases (AD/PD). This book
contains 56 papers written by selected authors, who had presented their research at the
Ninth International Conference on Alzheimer’s and Parkinson’s Diseases: Advances,
Concepts & New Challenges (AD/PD 2009), that took place on March 11-15, 2009
in captivating Prague, in the Czech Republic. The official proceedings (OP) of the
Conference will be published early in 2010 by Karger, as a special issue of the journal
The Prague meeting included over 2,300 scientific participants, and was the venue
for several hundred invited talks, general talks, posters, and symposia. It was impossible
to include all of the important scientific information presented at the meeting under one
cover while, at the same time, meeting publishers’ cost and profit considerations. We,
the co-organizers, therefore decided to restrict contributions to be published in the OP, to
chapters based on ORAL, INVITED presentations at the meeting.
We also agreed that Medimond International Proceedings (Medimond) would publish
a complementary book to the OP, based on FREE PAPERS presented at the Congress. This
additional publication, to be issued in printed volume and CD Rom format, would expand
the scope of available scientific information from the AD/PD 2009 proceedings.
Medimond’s policy is to provide rapid publication of conference proceedings. We,
therefore, agreed with this publisher’s request that we, the editors, would only correct
major mistakes or errors in scientific logic and fact. We would not concern ourselves
with stylistic differences in expression by authors whose first language is other than
English, nor with differences in font type, style, or referencing in these chapters. We
have also not been too particular in the choice of chapters included in the book, in order
to encourage diversity in the topics presented. Each author is solely responsible for the
information provided in his/her chapter. The manuscripts have, nevertheless, received our
general overview, with minor editorial changes inserted where necessary, in the interest
of maintaining scientific integrity, while at the same time enabling the rapid publication
of these findings. We trust that this book (and the accompanying CD), together with the
OP, will provide the reader with a broader overview of the scope and richness of the
Thus, in summary, we have agreed to allow Medimond to approach participants in
the ADPD conference whom we, as co-organizers, were unable to invite to contribute a
paper because of limitations in the size of the OP of the conference. In this manner, other
scientists would at least have the opportunity to publish their work in this Medimond
publication which, while a private product (hence each contributor to this volume was
required to pay a fee for publication), will be associated in name with the ADPD meeting.
The papers have been scrutinized by us for quality before we approved this publication.
Moreover, we would like to emphasize, as a disclaimer, that neither the ADPD meeting
co-organizers, nor Kenes received any compensation whatsoever from Medimond for
this product. This book is entirely a profit generator for Medimond, with the stipulation
that we, the co-organizers, must give the product our stamp of approval before it can be
A thorough and extensive, peer-reviewed editorial process will be employed in the
case of the OP document, which is presently in preparation.
Abraham Fisher, Ph.D. Israel Hanin, Ph.D.
Cho Hyun, M.D., Kwon Jee-Hyun, M.D., Kim Seon-Young, M.D. .
P300 response in early DLB and AD patients shows different topographic
Bonanni L., Iorio E., Onofrj M., Tiraboschi P., Anzellotti F., Franciotti R., Manzoli L.,
Visual Art Improves Communication and Behaviour of AD Patients
Musella O., Carloni A., De Marino L., Di Bartolo E., Gaeta G., Di Maggio P.
Prenatal Diesel Exhaust Exposure Causes Neurodegenerative Diseases in
Theory of mind and executive abilities in individuals with Parkinson’s disease
Costa A., Oliveri M., Torriero S., Peppe A., Martini M., Coletta K., Carlesimo G. A.,
An update on EHT 0202 preclinical and clinical development for Alzheimer’s
Polymorphisms of chemokine and chemokine receptor genes in Alzheimer’s
Reale M., GattaV., Di Nicola M., Stuppia L., Palka G., Iarlori C., Thomas A., Onofrj M.,
Management of severe psychotic symptoms associated with Parkinson disease
that needed a treatment in the psychiatric ward.
Joki Hideto, MD; Endo Masanao, MD; Tachiyama Tetsuya, MD; Kimura Katsuo, MD;
Nomiya Tamaki, MD; Shimamura Megumi, MD; Yamada Hitoshi, MD; Takahashi Tatsuya, MD;
Italian Olfactory Identification Test (IOIT): a new quantitative test for the
olfactory function. Results in patients with Parkinson’s disease.
Maremmani C., Marini P., Ramat S., Purcaro C., Napolitano A., Vanni P., Serra P., Morano P.,
Palumbo V., Orsini M., Marconi R., Rossi G., Meco G. .
New Trends in Alzheimer and Parkinson Disorders
Immune studies in peripheral blood of patients with alzheimer’s disease
Lombardi V.R.M., Etcheverría I., Fernández-Novoa L., Seoane S., Cacabelos R. .
CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish
Llovo R., Tudoli I., Carril J.C, Fernández-Novoa L., Seoane S. and Cacabelos R. .
Gender aspects in Mild cognitive Impairment (MCI) to Alzheimer’s Disease
(AD) conversion. A Romanian epidemiological study.
Spiru L., Ioancio I., Nuta C., Turcu I. .
Aging, Neurodegenerative Disease and β-Secretase
Murphy M.P., Ahmed R.R., Webb R.L., Holler C.J., Li F., Beckett T.L., Niedowicz D.M.,
Polygenic risk factors related to neurodegenration in Alzheimer disease: cal-
culation of a genetic predisposition score (gps)
Fernández-Novoa L., Llovo R., Tudoli I., Seoane S. and Cacabelos R. .
Multiple system atrophy and Alzheimer’s disease in association: coincidence
A pilot, comparative epigenomic and metabolomic study in healthy elderly,
Cucu N., Anton G., Radu LG, Turcu I., Spiru L. .
The PARS Study: Evaluating pre-motor Parkinson disease
Jennings Danna, Siderowf Andrew, Stern Matthew, Marek Kenneth
Logistic regression as a useful tool to explain genetic risk of stroke
Carril JC., Llovo R., Fernández-Novoa L., Cacabelos R. .
The effect of combination therapy of dopamine agonists for Parkinson’s di-
Nakamura Shinichiro, Kitami Makiko, Furukawa Yoshiyuki .
ACE-R: cross-sectional and longitudinal use for cognitive assessment
Larner AJ. . 103Evidence for lipid alterations in lipid rafts from alzheimer´s disease human
Díaz M., Martín V., Fabelo N., Santpere G., Puig B., Marín R., Alonso R., Gómez T., Pérez J.A.
and Ferrer I. . 109The effect of glycosaminoglycans (gags) on amyloid formation and aggregate
Vilasi S., Irace G., Sirangelo I. . 115Effects of donepezil in patients with various type of dementia
Asano S., Toyoda T., Yonekura I., Shimada S., and Tanishima T. . 123
Arguments for the reconsideration of procaine as a potent therapeutic molecule
Turcu I., Spiru L. . 127Marine natural products as aβ modulators
García-Palomero E., Usán P., García P., Delgado E., de Austria C., Sáiz G., Pérez M.A.,
Sánchez-Quesada J., Dorronsoro I., Castro A. and Medina M. . 135Mixture of ferulic acid and garden angelica extract improves cognitive function
Nakamura S., Sasaki K., Azekawa T., Itami A., Ito T., Kiyohara T., Kono K., Matsuda S.,
Mizuno Y., Miyahara S., Origasa H., Endo H., Yanagimachi A., Lee HS . 141Xanomeline binding to and activation of muscarinic receptors.
Jakubík J., Machová E., El-Fakahany E.E., and Dolezˇal V. . 145TGF-β1-induced TIAF1 self-association leads to apoptosis
Lee M.H., Lin S.R., Chang N.S. . 149Protofibrillar amyloid-beta down-regulates brain-derived neuro-trophic factor
Fahnestock M., Peng S., Marchese M., Garzon D., and Mufson E.J. . 157Endothelial damage and platelet activation in Alzheimer’s disease patients
Piazza F., Galimberti G., Conti E., Guerrato I., Isella V., Speranza T., Borroni B., Pogliani E.M.,
Padovani A. and Ferrarese C. . 163Cholesterol modulates amyloid beta peptide 1-42 channel formation in planar
Meleleo D., Notarachille G., Gallucci E. and Micelli S. . 167Effect of calcium and cadmium ions on amyloid beta peptide 1-42 channel
Notarachille G., Meleleo D., Gallucci E., Micelli S. . 173Role of nitric oxide in the aβ
Limón I.D., Díaz A., Mendieta L., Guzmán A., Martínez I., Espinosa B., Zenteno E.
and Guevara J. . 179Presenilin 1 mediates cell-cell adhesion in transfected L-fibroblasts
Schwarzman A., Sarantseva S., Soloviev K., Talalaeva E., and Vitek M.P. . 187Sirtuins as a link between ageing and neurodegeneration
Marques Oldriska, Oliveira Rita M., Moita Luis Ferreira, and Outeiro Tiago Fleming . 191Neuronal Abnormality Topography and Discrimination of MCI developing
Musha T. and Matsuzaki H. . 199GDNF and IGF-1-induced Astrocytic Metallothionein-1 (MT-1) and -2 (MT-2)
New Trends in Alzheimer and Parkinson Disorders
The homozygous weaver mouse as an animal model of parkinson’s disease
Martí J., Santa-Cruz MC., Serra R., Molina V. and Hervás JP. . 213Deletion of the gene encoding for the enzyme Methionine sulphoxide reductase
A increases the toxicity of Aβ (1-42) in an in vivo model.
Minniti A., Inestrosa N. and Aldunate R. . 217Effects of copper on Aβ-induced pathological features in Caenorhabditis ele-
Minniti A., Rebolledo D., Inestrosa N. . 221Anti-β-amyloid (Aβ) IgG levels in plasma of healthy people measured with a
Weber A., Minibeck E., Engelmaier A., Ehrlich H. J., Schwarz H. P. . 225Neuromodulatory actions of beta-amyloid on the DA release
Mura E., Preda S., Govoni S., Frattini P., Grilli M., Marchi M. . 229Neurofibrillary pathology in the brainstem of the tau mutant pR5 mouse
Schröder H., Götz J., Pilz K., Kuhlage S., de Vos R.A.I., Bauer T., Selzer A., Köhler C. . 233Microfluidic system with integrated magnetic carrier for immunoprecipitation
Jankovicova B., Zverinova Z., Mohamadi R., Slovakova M., Hernychova L., Faigle W.,
Viovy J.-L., Bilkova Z. . 239Overexpression of human amyloid precursor protein causes neurodegeneration
and loss of synaptic proteins in transgenic Drosophila
Sarantseva S., Bolshakova O., Timoshenko S., Vitek M., and Schwarzman A. . 245 The Avian Ciliary Ganglion: A useful model for study of the effects of beta amyloid on neurotransmitter release
Mazalan Susan, Hart Elizabeth, & Gray D. Bruce . 249Monitoring of Aβ fibrillization using an improved fluorimetric method.
Karafin A., Palumaa P. and Tõugu V. . 255Alzheimer’s β-amyloid deposits induce the c-Abl/p73 signaling in AD mo-
Cancino G.I., Alvarez A.R. . 261Modified embryo organ culture model system for preclinical studies of growth
factors-induced neural tissue differentiation in mammals
Stipic´ J. and Crnek-Kunstelj V. . 267The changes in the lipid phase of brain cell membranes in mice bearing expe-
rimental Alzheimer’s-like disease induced with the help of olfactory bulbec-
Burlakova E., Molochkina E., Gerasimov N., Goncharova I., Fatkullina L., Goloschapov A. 273Effect of Proteasome Inhibition on MPP+-induced GSTP1 Expression in
Neves Carvalho A., Marques C., Rodrigues E., Pereira P., Gama M. J. . 279
Doxycycline, a 2nd generation tetracycline, protects neuronal cells against
glutamate- but not against 6-OHDA-induced cytotoxicity
Viana G. B., Nobre-Jr H. V., Calou I. B., Garcia F. A., Leal L.K. A.M. and Andrade G. M. . 289Developmental changes in calcium channels and D -like receptors involved in
the glutamatergic transmission onto rat basal forebrain cholinergic neurons
Momiyama T. . 299Aβ causes memory impairment by disturbing the jak2/stat3 axis in hippocampal
Chiba T., Yamada M., and Aiso S. . 307Dual Roles Of Amyloid-Beta And Secreted Forms Of Amyloid Precursor
Luo J.J., Kusiak J., Wallace M., Wallace W.C. . 311Link between Gangliosides, Sphingolipids and Alzheimer’s Disease
Grimm M.O.W., Grösgen S. and Hartmann T. . 317
Abiraterone Acetate Tablets 250 mg XBIRA COMPOSITION Each tablet contains: Abiraterone Acetate ……… 250 mg Excipients……………………….q.s. DOSAGE FORM Tablet PHARMACOLOGY Pharmacodynamics Mechanism of Action Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17alpha-hydroxylase/C17,20-lyase (CYP17). T
HEALTH ALERT TO HEALTHCARE PROVIDERS, HOSPITALS LABORATORIES, CLINICAL LABORATORIES, AND PHARMACISTS Fungal endophthalmitis following use of products from Franck’s Compounding Pharmacy The Los Angeles County Department of Public Health (LAC DPH) has identified 2 outbreaks of fungal endophthalmitis infections following intraocular use of products from Franck’s Compound